Higher dose intra-arterial milrinone and intra-arterial combined milrinone-nimodipine infusion as a rescue therapy for refractory cerebral vasospasm

• Published in: Interventional neuroradiology 2017-12, Vol.23 (6), p.636-643
• Main Authors: Duman, Enes, Karakoç, Fatma, Pinar, H Ulas, Dogan, Rafi, Fırat, Ali, Yıldırım, Erkan
• Format: Article
• Language: English
• Subjects: Aneurysm; Angiography, Digital Subtraction; Cerebral Angiography; Computed Tomography Angiography; Drug Therapy, Combination; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Milrinone - administration & dosage; Nimodipine - administration & dosage; Retrospective Studies; Subarachnoid Hemorrhage - complications; Treatment Outcome; Vasodilator Agents - administration & dosage; Vasospasm, Intracranial - diagnostic imaging; Vasospasm, Intracranial - drug therapy; Vasospasm, Intracranial - etiology
• ISSN: 1591-0199; 2385-2011
• DOI: 10.1177/1591019917732288

Background Cerebral vasospasm (CV) is a major cause of delayed morbidity and mortality in patients with subarachnoid hemorrhage (SAH). Various cerebral protectants have been tested in patients with aneurysmal SAH. We aimed to research the success rate of treatment of CV via intra-arterial milrinone injection and aggressive pharmacological therapy for refractory CV. Methods A total of 25 consecutive patients who received intra-arterial milrinone and nimodipine treatment for CV following SAH between 2014 and 2017 were included in the study. Patients who underwent surgical clipping were excluded. Refractory vasospasm was defined as patients with CV refractory to therapies requiring ≥3 endovascular interventions. Overall, six patients had refractory CV. Long-term neurological outcome was assessed 6–18 months after SAH using a modified Rankin score and Barthel index. Results The median modified Rankin scores were 1 (min: 0, max: 3) and Barthel index scores were 85 (min: 70, max: 100) From each vasospastic territory maximal 10–16 mg milrinone was given to patients; a maximum of 24 mg milrinone was given to each patient in a session and a maximum of 42 mg milrinone was given to a patient in a day. Both milrinone and nimodipine were given to three patients. There was a large vessel diameter increase after milrinone and nimodipine injections. No patient died due to CV; only one patient had motor dysfunction on the right lower extremity. Conclusion Higher doses of milrinone can be used effectively to control refractory CV. For exceptional patients with refractory CV, high dose intra-arterial nimodipine and milrinone infusion can be used as a rescue therapy.